ClinicalTrials.gg
CompletedNCT01725009Updated Mar 29, 2013

Multiple-dose Study of Levetiracetam Injection in Japanese and Caucasian Healthy Males

A Phase 1 interventional study of Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Healthy Volunteers, sponsored by UCB Japan Co. Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-03-29.

Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

To compare the pharmacokinetics of levetiracetam following single and multiple 15-minute intravenous infusions of 1500 mg levetiracetam between Japanese and Caucasian healthy male subjects

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteers
  • Japanese
  • Caucasian
03

In context

Lead sponsor

UCB Japan Co. Ltd. is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy Japanese and Caucasian males with the age between 20 and 40 years old,
  • with the between 20 and 25,
  • with the body weight between 60 and 80kg

Exclusion criteria

Exclusion Criteria:

  • subjects who have a history or presence of drug addiction or excessive use of alcohol
  • current smokers and former smokers who have given up since less than 6 months before the first dose
  • heavy caffeine drinker
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Levetiracetam IV infusions in Japanese

    Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Japanese subjects

    Drug: Multiple 15-minute intravenous infusions of 1500 mg levetiracetam

  • Experimental
    Levetiracetam IV infusions in Caucasian

    Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Caucasian subjects

    Drug: Multiple 15-minute intravenous infusions of 1500 mg levetiracetam

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration after a single dose (Cmax)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of Intravenous (IV) infusion

  2. Area under the curve from zero to the time of the last quantifiable concentration after a single (AUC(0-t))

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion

  3. Area under the plasma concentration time curve from zero to infinity after a single dose (AUC)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion

  4. Body-weight normalized maximum plasma concentration after a single dose (Cmax)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion

  5. Body-weight normalized area under the curve from zero to the time of the last quantifiable concentration after a single, (AUC(0-t))

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion

  6. Body weight normalized area under the plasma concentration time curve from zero to infinity after a single dose, (AUC)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion

  7. Maximum plasma concentration at steady state after multiple doses (Cmax,ss)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion.

  8. Area under the curve over a dosing interval at steady state after multiple doses (AUCτss)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion.

  9. Body-weight normalized maximum plasma concentration at steady state after multiple doses (Cmax,ss)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion.

  10. Body-weight normalized area under the curve over a dosing interval at steady state after multiple doses (AUCτss)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion.

Secondary outcomes

  1. Area under the curve over a dosing interval, (AUCτ (τ = 12 hours))

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion

  2. Time to maximum plasma concentration after a single dose (tmax)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion.

  3. Terminal elimination half-life after a single dose (t1/2)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion.

  4. First order terminal elimination rate constant after a single dose (λz)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion.

  5. Total body clearance after a single dose (CL)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion.

  6. Volume of distribution during terminal phase after a single dose (Vz)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion.

  7. Mean residence time after a single dose (MRT)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion.

  8. Time to maximum plasma concentration at steady state after multiple doses (tmax,ss)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion.

  9. Total body clearance at steady state after multiple doses (CLss)

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion.

  10. Linearity factor after multiple doses (LF)

    LF = AUCτss / AUC

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of the first IV infusion and at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of the last IV infusion.

  11. Accumulation ratio (RAUC) after multiple doses

    RAUC = AUCτss / AUCτ

    Time frame: Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of the first and the last IV infusions

07

Study locations

1 site
  • 01
    Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2012
First posted
Nov 12, 2012
Start
Oct 2012
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Last update
Mar 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01725009
Lead sponsor
UCB Japan Co. Ltd.
Responsible party
Sponsor
First posted
Nov 12, 2012
Start date
Oct 2012
Primary completion
Dec 2012
Completion
Dec 2012
Last update
Mar 29, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion